Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 13/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9439408 | 0.89 | CYP3A4 (0.51) | CYP3A4NAMPTCTSSCTSLCTSB | |
| SCHEMBL4082666 | 0.88 | CTSS (0.53) | CYP3A4CTSSCTSLCTSBCTSK | |
| SCHEMBL11853949 | 0.88 | CTSS (0.53) | CYP3A4CTSSCTSLCTSBCTSK | |
| SCHEMBL11860523 | 0.85 | CTSS (0.51) | CYP3A4CTSSCTSLCTSBCTSK | |
| SCHEMBL11860510 | 0.85 | CTSS (0.51) | CYP3A4CTSSCTSLCTSBCTSK | |
| SCHEMBL6737619 | 0.82 | CYP3A4 (0.49) | CYP3A4NAMPTCTSSCTSLCTSB | |
| SCHEMBL1275003 | 0.80 | CYP3A4 (0.71) | CYP3A4NAMPTALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL11860454 | 0.78 | CTSS (0.51) | CTSSCTSLCTSBCTSK | |
| SCHEMBL11860445 | 0.78 | CTSS (0.51) | CTSSCTSLCTSBCTSK | |
| SCHEMBL30336917 | 0.77 | CYP3A4 (0.53) | CYP3A4NAMPTRAB9ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | CYP3A4 2536/4885NAMPT 10/4885CTSS 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.